

***BCR::ABL1*, p210, mRNA Detection, Reverse Transcription-PCR (RT-PCR), Quantitative, Monitoring Chronic Myeloid Leukemia (CML), Varies**

Test ID: BCRAB

Explanation: Ordering guidance will be updated on the effective date to include the newly available monitoring test, BARQ.

New Ordering Guidance

This test is intended for monitoring patients with known e13/a2 or e14/a2 *BCR::ABL1* (p210) fusion forms.

This test **should not** be used to screen for *BCR::ABL1* fusions at the time of diagnosis.

To screen for *BCR::ABL1* fusions at the time of diagnosis, order one of the following:

- BADX / *BCR::ABL1*, Qualitative, Diagnostic Assay, Varies
- BCRFX / *BCR::ABL1* Qualitative Diagnostic Assay with Reflex to *BCR::ABL1* p190 Quantitative Assay or *BCR::ABL1* p210 Quantitative Assay, Varies .

To monitor patients carrying *BCR::ABL1* fusion forms coding for the p190 (e1/a2) protein, order BA190 / *BCR::ABL1*, p190, mRNA Detection, Reverse Transcription-PCR (RT-PCR), Quantitative, Monitoring Assay, Varies.

To monitor patients carrying rare *BCR::ABL1* fusion forms coding for e19a2, e13/e14a3, e1a3, e6a2, e19a3, e8a2, e12a2, e6a3, e8a3, and e12a3, order BARQ / *BCR::ABL1*, Rare Fusion Monitoring, Quantitative, Varies.

If the patient has a negative history for p210 but has positive history of p190 or a rare fusion form, this test will be cancelled, and one of the following appropriate monitoring tests will be added:

- BA190 / *BCR::ABL1*, p190, mRNA Detection, Reverse Transcription-PCR (RT-PCR), Quantitative, Monitoring Assay, Varies
- BARQ / *BCR::ABL1*, Rare Fusion Monitoring, Quantitative, Varies

Questions

Contact Melissa Lonzo, Laboratory Resource Coordinator at 800-533-1710.